ArticleFrontiers in pharmacology2025
Case Report: Photodynamic therapy meets Chinese herbal medicine: a promising approach for advanced hypopharyngeal carcinoma.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypopharyngeal squamous cell carcinoma (HPSCC) continues to have the bleakest prognosis among head and neck cancers. Managing inoperable HPSCC, particularly in elderly patients, presents a complex therapeutic challenge. This case details an 84-year-old female with advanced recurrent HPSCC and a complex medical history was treated using photodynamic therapy (PDT) combined with Chinese herbal medicine (CHM). She was presented with a hemorrhagic mandibular mass. PDT was administered due to her inability to undergo surgery. Despite significant side effects such as erythema and swelling from PDT, these were effectively managed with the external application of the CHM formula Jiedu Zhitong Powder, which alleviated pain and inflammation. The treatment led to a decrease in tumor size, resolution of ulceration and hemorrhage, and improved hemoglobin levels, allowing the patient to be discharged. Regular follow-ups showed no recurrent bleeding, although she eventually succumbed to complications related to tumor progression 7 months post-treatment. This case highlights the potential benefits of integrating PDT with CHM in treating unresectable HPSCC. The successful management of PDT side effects with CHM could represent a promising avenue for enhancing patient tolerance and adherence to treatment in HPSCC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.